Patents by Inventor Li-Huei Tsai

Li-Huei Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220184614
    Abstract: A flow cell includes: a first substrate; a second substrate; a first resin layer disposed over an inner surface of the first substrate; a second resin layer disposed over an inner surface of the second substrate; a first plurality of biological capture sites located at the first resin layer; a second plurality of biological capture sites located at the second resin layer; and a polymer layer interposed between the first resin layer and the second resin layer, such that the first substrate is attached to the second substrate via at least the first resin layer, the polymer layer, and the second resin layer, wherein the polymer layer defines a plurality of microfluidic channels that extend through polymer layer.
    Type: Application
    Filed: February 28, 2022
    Publication date: June 16, 2022
    Applicant: Illumina, Inc.
    Inventors: Shang-Ying TSAI, Li-Min Hung, Jung-Huei Peng, Shane Bowen, Hui Han, Danny Chan, Sang Park
  • Publication number: 20220151864
    Abstract: A method of treating neurodegeneration in a subject that includes administering a non-invasive tactile stimulus having a stimulus frequency of about 30 Hz to about 50 Hz to a subject to induce synchronized gamma oscillations in at least one portion of the peripheral nervous system of the subject, of the spinal cord of the subject, or both.
    Type: Application
    Filed: November 19, 2021
    Publication date: May 19, 2022
    Applicant: Massachusetts Institute of Technology
    Inventors: Li-Huei Tsai, Ho-Jun SUK, Guojie Xu, Arit Banerjee
  • Publication number: 20220127581
    Abstract: The present disclosure provides, in some embodiments, in vitro brain (miBRAIN) having functional and structural properties of in vivo brain as well as methods of identifying compounds capable of influencing brain function.
    Type: Application
    Filed: August 27, 2021
    Publication date: April 28, 2022
    Applicant: Massachusetts Institute of Technology
    Inventors: Li-Huei Tsai, Joel Blanchard, Alice Stanton, Adele Bubnys, Robert S. Langer
  • Publication number: 20220090021
    Abstract: The present disclosure provides, in some embodiments, in vitro blood brain barrier (iBBB) having functional properties of in vivo BBB as well as methods of identifying compounds capable of traversing the iBBB. Compounds capable of crossing the iBBB and therapeutic uses of such compounds are also described.
    Type: Application
    Filed: January 22, 2020
    Publication date: March 24, 2022
    Applicant: Massachusetts Institute of Technology
    Inventors: Li-Huei Tsai, Joel Blanchard
  • Publication number: 20220064151
    Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome.
    Type: Application
    Filed: August 9, 2021
    Publication date: March 3, 2022
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
  • Publication number: 20220040496
    Abstract: Devices, systems, and methods for treating dementia or Alzheimer's disease in a subject in need thereof. In one example, chronic visual stimuli having a frequency of about 30 Hz to about 50 Hz, and more specifically about 40 Hz, are non-invasively delivered to the subject to entrain gamma oscillations in multiple brain regions of the subject, including the prefrontal cortex (PFC) and the hippocampus. The entrained gamma oscillations modulate neuronal activity across multiple brain regions (e.g., facilitate functional binding of neural networks at low gamma frequencies) to induce various neuroprotective effects (e.g., amelioration of amyloid plaques and tau hyper-phosphorylation) and reduce neurodegeneration. Neuronal activity mediated by the chronic visual stimuli reduces an immune response in microglia and ameliorates aberrantly modified genes and proteins involved in membrane trafficking, intracellular transport, synaptic function, neuroinflammation and DNA damage response.
    Type: Application
    Filed: March 30, 2021
    Publication date: February 10, 2022
    Inventors: Chinnakkaruppan Adaikkan, Li-Huei Tsai
  • Patent number: 11241586
    Abstract: Devices, systems, and methods for a treating dementia or Alzheimer's disease in a subject in need thereof. In one example, combined auditory and visual stimuli having a frequency of about 20 Hz to about 60 Hz, and more specifically about 40 Hz, are non-invasively delivered to the subject to induce synchronized gamma oscillations in at least one brain region of the subject. In particular, pursuant to various treatment and exposure protocols, combined auditory and visual stimulation (as opposed to auditory or visual stimulation alone) promotes a microglia response in the medial prefrontal cortex (mPFC). More generally, combined auditory and visual stimulation induces an extended microglia clustering response in the auditory cortex, the visual cortex, and the mPFC.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: February 8, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Li-Huei Tsai, Anthony James Martorell, Ho-Jun Suk, Ed Boyden
  • Patent number: 11180438
    Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 23, 2021
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Li-Huei Tsai, Stephen J. Haggarty, Debasis Patnaik, Ping-Chieh Pao
  • Publication number: 20210353566
    Abstract: The invention relates to methods of using choline supplementation for treating APOE4-related disorders. In particular the methods are accomplished by administering choline treatment paradigms to re-establish lipid homeostasis in APOE4 carriers.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 18, 2021
    Applicants: Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research
    Inventors: Li-Huei Tsai, Yuan-Ta Lin, Julia Bonner, Priyanka Narayan, Grzegorz Sienski
  • Patent number: 11084803
    Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 10, 2021
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
  • Publication number: 20210171429
    Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 10, 2021
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Li-Huei Tsai, Stephen J. Haggarty, Debasis Patnaik, Ping-Chieh Pao
  • Patent number: 10960225
    Abstract: Devices, systems, and methods for treating dementia or Alzheimer's disease in a subject in need thereof. In one example, chronic visual stimuli having a frequency of about 30 Hz to about 50 Hz, and more specifically about 40 Hz, are non-invasively delivered to the subject to entrain gamma oscillations in multiple brain regions of the subject, including the prefrontal cortex (PFC) and the hippocampus. The entrained gamma oscillations modulate neuronal activity across multiple brain regions (e.g., facilitate functional binding of neural networks at low gamma frequencies) to induce various neuroprotective effects (e.g., amelioration of amyloid plaques and tau hyper-phosphorylation) and reduce neurodegeneration. Neuronal activity mediated by the chronic visual stimuli reduces an immune response in microglia and ameliorates aberrantly modified genes and proteins involved in membrane trafficking, intracellular transport, synaptic function, neuroinflammation and DNA damage response.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: March 30, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Chinnakkaruppan Adaikkan, Li-Huei Tsai
  • Publication number: 20200316335
    Abstract: A method includes administering a non-invasive stimulus to a subject having a frequency of about 35 Hz to about 45 Hz to induce synchronized gamma oscillations in at least one brain region of the subject.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 8, 2020
    Inventors: Li-Huei Tsai, Emery Brown, Hannah Iaccarino, Anthony James Martorell, Chinnakkaruppan Adaikkan
  • Publication number: 20200316334
    Abstract: A method includes administering a non-invasive stimulus to a subject having a frequency of about 35 Hz to about 45 Hz to induce synchronized gamma oscillations in at least one brain region of the subject.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 8, 2020
    Inventors: Li-Huei Tsai, Emery Brown, Hannah Iaccarino, Anthony James Martorell, Chinnakkaruppan Adaikkan
  • Patent number: 10682490
    Abstract: A method includes administering a non-invasive stimulus to a subject having a frequency of about 35 Hz to about 45 Hz to induce synchronized gamma oscillations in at least one brain region of the subject.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: June 16, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Li-Huei Tsai, Emery Brown, Hannah Iaccarino, Anthony James Martorell, Chinnakkaruppan Adaikkan
  • Patent number: 10662199
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: May 26, 2020
    Assignees: The Broad Institute, Inc., The General Hospital Corporation, Massachusetts Institute of Technology
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
  • Publication number: 20200087236
    Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.
    Type: Application
    Filed: June 15, 2018
    Publication date: March 19, 2020
    Applicant: The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Li-Huei TSAI, Stephen J. HAGGARTY, Debasis PATNAIK, Ping-Chieh PAO
  • Publication number: 20190240443
    Abstract: A method includes administering a non-invasive stimulus to a subject having a frequency of about 35 Hz to about 45 Hz to induce synchronized gamma oscillations in at least one brain region of the subject.
    Type: Application
    Filed: April 4, 2019
    Publication date: August 8, 2019
    Inventors: Li-Huei Tsai, Emery Brown, Hannah Iaccarino, Anthony James Martorell, Chinnakkaruppan Adaikkan
  • Publication number: 20190211000
    Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 11, 2019
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
  • Publication number: 20190126062
    Abstract: Devices, systems, and methods for treating dementia or Alzheimer's disease in a subject in need thereof. In one example, chronic visual stimuli having a frequency of about 30 Hz to about 50 Hz, and more specifically about 40 Hz, are non-invasively delivered to the subject to entrain gamma oscillations in multiple brain regions of the subject, including the prefrontal cortex (PFC) and the hippocampus. The entrained gamma oscillations modulate neuronal activity across multiple brain regions (e.g., facilitate functional binding of neural networks at low gamma frequencies) to induce various neuroprotective effects (e.g., amelioration of amyloid plaques and tau hyper-phosphorylation) and reduce neurodegeneration. Neuronal activity mediated by the chronic visual stimuli reduces an immune response in microglia and ameliorates aberrantly modified genes and proteins involved in membrane trafficking, intracellular transport, synaptic function, neuroinflammation and DNA damage response.
    Type: Application
    Filed: October 10, 2018
    Publication date: May 2, 2019
    Inventors: Chinnakkaruppan ADAIKKAN, Li-Huei Tsai